T1	Intervention 101 157	women with ErbB2 overexpressing metastatic breast cancer
T2	Intervention 232 400	patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who have progressed on prior trastuzumab in the metastatic setting
T3	Intervention 648 675	eligible patients (N = 112)
